The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Early Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Biological: TCR-T Cells Injection
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06904859
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06644443
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Astragalus + Gemcitabine
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06234072
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
Not Applicable
Recruiting
- Conditions
- Advanced Gastric CarcinomaAdvanced Pancreatic Carcinoma
- Interventions
- Biological: Claudin18.2 CAR-T cells
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05620732
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
Not Applicable
Recruiting
- Conditions
- T Lymphoblastic Leukemia/Lymphoma
- Interventions
- Biological: CD7 CAR-T cells
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05620680
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
Not Applicable
Recruiting
- Conditions
- Advanced Soft-tissue Sarcoma
- Interventions
- Biological: NY-ESO-1 TCR-T
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05620693
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Biological: GPC3 CAR-T cells
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05620706
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Phase 1
- Conditions
- Relapse LeukemiaRefractory Leukemia
- Interventions
- Biological: Allogeneic CD19 CAR-T cells
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05164042
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease
Phase 1
- Conditions
- Graft Vs Host Disease
- Interventions
- Biological: Umbilical Cord Mesenchymal Stem Cell Therapy
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05152160
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
Phase 1
- Conditions
- Relapse Multiple MyelomaMultiple MyelomaRefractory Multiple Myeloma
- Interventions
- Biological: BCMA CAR-T cells
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05150522
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath